The Sound of Evolution
Adalimumab
Mechanism of action:
Adalimumab is a monoclonal antibody that binds to tumor necrosis factor-α (TNF-α). TNF-α is a cytokine that plays a central role in chronic inflammatory responses by promoting inflammatory cell activation and tissue destruction. By blocking the binding of TNF-α to its receptors (TNFR1 and TNFR2), adalimumab suppresses the downstream inflammatory cascade.
Reference(s):
1. Lorenz HM et al. (2002). Technology evaluation: adalimumab, Abbott laboratories. Curr Opin Mol Ther.
2. Flendrie M et al. (2003). Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis.
3. Aguillon JC et al. (2003). New immunological weapons for medicine in the 21st Century: biological therapy based on the use of the latest generation monoclonal antibodies. Rev Med Chil.